Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 9/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3847435 | 0.99 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Bromide SCHEMBL3847332 | 0.99 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7074124 | 0.79 | NPC1 (0.43) | KMT2AMEN1POLBGAAALDH1A1 | |
| SCHEMBL6936037 | 0.79 | GSK3B (0.44) | MAPTKMT2AMEN1GAAALDH1A1 | |
| SCHEMBL6935144 | 0.79 | GSK3B (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8390047 | 0.78 | ALDH1A1 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Bromide SCHEMBL3847336 | 0.77 | NPC1 (0.42) | KMT2AMEN1POLBGAAALDH1A1 | |
| Bromide SCHEMBL2947798 | 0.77 | RAB9A (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Bromide SCHEMBL4114709 | 0.77 | RAB9A (0.46) | MAPTKMT2AMEN1GAAALDH1A1 | |
| Bromide SCHEMBL122634 | 0.77 | ALDH1A1 (0.43) | MAPTKMT2AMEN1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144570-B2 | Sunscreen compositions and methods of use thereof | ALTEON, INC. (US) | 2006-12-05 | — | — | US | claimed |
| US-7078022-B2 | Sunscreen compositions and methods of use thereof | AVON PRODUCTS, INC. (US) | 2006-07-18 | — | — | US | claimed |
| US-20050063924-A1 | Sunscreen compositions and methods of use thereof | SYNVISTA THERAPEUTICS, INC. | 2005-03-24 | — | — | US | claimed |
| US-20040120905-A1 | Sunscreen compositions and methods of use thereof | SYNVISTA THERAPEUTICS, INC. | 2004-06-24 | — | — | US | claimed |
| WO-2003099249-A1 | SUNSCREEN COMPOSITIONS AND CONTAINING AZOLIUM COMPOUNDS | ALTEON, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| WO-2003099241-A2 | SUNSCREEN COMPOSITIONS AND METHODS OF USE THEREOF | MANISCALCO TONY (US) | 2003-12-04 | — | — | WO | claimed |
| EP-0808163-B1 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC (US) | 2003-07-23 | — | — | EP | claimed |
| US-6007865-A | FOR INHIBITING AND REVERSING NONENZYMATIC CROSS-LINKING (PROTEIN AGING), TREATING KIDNEY DAMAGE AND TREATING COMPLICATIONS OF DIABETES, PREVENTING FOOD SPOILAGE | ALTEON INC. | 1999-12-28 | — | — | US | claimed |
| EP-2384193-B1 | VITAMIN D PROMOTING SUNSCREEN | ARMSTRONG ERNEST T (US) | 2025-08-06 | — | — | EP | disclosed |
| US-9724544-B2 | Vitamin D promoting sunscreen | Armstrong, Ernest T. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-2384193-A2 | VITAMIN D PROMOTING SUNSCREEN | Armstrong, Ernest T. (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110268678-A1 | VITAMIN D FORMING SUNSCREEN | ARMSTRONG ERNEST T | 2011-11-03 | — | — | US | disclosed |
| WO-2010076731-A2 | VITAMIN D PROMOTING SUNSCREEN | ARMSTRONG ERNEST T (US) | 2010-07-08 | — | — | WO | disclosed |
| US-7144570-B2 | Sunscreen compositions and methods of use thereof | ALTEON, INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20050063924-A1 | Sunscreen compositions and methods of use thereof | SYNVISTA THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20040120905-A1 | Sunscreen compositions and methods of use thereof | SYNVISTA THERAPEUTICS, INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2003099241-A3 | SUNSCREEN COMPOSITIONS AND METHODS OF USE THEREOF | MANISCALCO TONY (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2003099249-A1 | SUNSCREEN COMPOSITIONS AND CONTAINING AZOLIUM COMPOUNDS | ALTEON, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099241-A2 | SUNSCREEN COMPOSITIONS AND METHODS OF USE THEREOF | MANISCALCO TONY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099241-A2 | SUNSCREEN COMPOSITIONS AND METHODS OF USE THEREOF | MANISCALCO TONY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040120905-A1 | Sunscreen compositions and methods of use thereof | TYR, TRPA1, SUN2 | HDAC3 1063/4885HDAC4 611/4885HDAC1 1117/4885 |
| US-20050063924-A1 | Sunscreen compositions and methods of use thereof | SUN2, CUTA, TYR | HDAC3 1571/4885HDAC4 810/4885HDAC1 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.